Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer
Status:
Terminated
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the anti-tumor activity (via objective response
rate) of alvespimycin in patients with breast cancer who have not previously received
trastuzumab (except as adjuvant therapy).